EnjaymoActive Ingredient(s): Sutimlimab-jome
FDA Approved: * February 4, 2022
Pharm Company: * BIOVERATIV THERAPEUTICS INC
Sutimlimab, sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD). It is given by intravenous infusion. Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro. This drug is being developed by Bioverativ, a Sanofi company. Sutimlimab was approved for medical use in the United Stat... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.
Enjaymo 50 mg/ml Intravenous Injection, Solution, ConcentrateNDC: 80203-347
Bioverativ U.S. LLC.